The Radiology of Osteoporotic Vertebral Fractures Revisited

Lentle, Brian C.; Koromani, Fjorda; Brown, Jacques P.; Oei, Ling; Ward, Leanne M.; Goltzman, David; Rivadeneira, Fernando; Leslie, William D.; Probyn, Linda; Prior, Jerilynn C.; Hammond, Ian; Cheung, Angela M.; Oei, Edwin H.G.

doi:10.1002/jbmr.3669

Cited by 79 publications

(61 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…at least I grade). However, the significance and predictive ability of grade I vertebral fractures for future fractures is still questioned (142).…”

Section: Discussionmentioning

confidence: 99%

DIAGNOSIS OF ENDOCRINE DISEASE: Evaluation of bone fragility in endocrine disorders

Eller-Vainicher

Falchetti

Gennari

et al. 2019

European Journal of Endocrinology

View full text Add to dashboard Cite

An underlying disease affecting bone health is present in up to 40 and 60% of osteoporotic postmenopausal women and men respectively. Among the disorders leading to a secondary form of osteoporosis, the endocrine diseases are highly represented. A frequent finding in patients affected with an endocrine-related forms of bone disease is that the skeletal fragility is partially independent of the bone density, since the fracture risk in these patients is related more to a reduction of bone quality than to a decrease of bone mass. As a consequence, bone mineral density evaluation by dual-X-ray absorptiometry may be inadequate for establishing the risk of fracture in the setting of the endocrine-related forms of osteoporosis. In the recent years, several attempts to non-invasively estimating bone quality have been done. Nowadays, some new tools are available in the clinical practice for optimising the fracture risk estimation in patients with endocrine disorders. The aim of this review is to summarise the evidence regarding the role of the different imaging tools for evaluating bone density and bone quality in the most frequent forms of endocrine-related osteoporosis, such as obesity, diabetes, acromegaly, thyrotoxicosis, primary hyperparathyroidism, hypercortisolism and hypogonadism. For each of these disorders, data regarding both the current available tools and the future possible new techniques for assessing bone fragility in patients with endocrine diseases are reported.

show abstract

“…at least I grade). However, the significance and predictive ability of grade I vertebral fractures for future fractures is still questioned (142).…”

Section: Discussionmentioning

confidence: 99%

DIAGNOSIS OF ENDOCRINE DISEASE: Evaluation of bone fragility in endocrine disorders

Eller-Vainicher

Falchetti

Gennari

et al. 2019

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Vertebral fractures were assessed from DXA scans using the quantitative morphometry method. Semiquantitative (SQ) gradings were not obtained . Vertebral height was measured at each evaluable level using six points in each vertebral body from T 7 to L 4 .…”

Section: Methodsmentioning

confidence: 99%

“…Semiquantitative (SQ) gradings were not obtained. (10) Vertebral height was measured at each evaluable level using six points in each vertebral body from T 7 to L 4 . The automatic vertebral morphometry was reviewed by two radiographers with 5 to 10 years of VFA experience, who corrected the marker placement manually if needed.…”

Section: Dxa Measures Of Bone Density and Prevalent And Incident Radimentioning

confidence: 99%

Greater Bone Marrow Adiposity Predicts Bone Loss in Older Women

Woods

Ewing

Sigurðsson

et al. 2019

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Bone marrow adiposity (BMA) is associated with aging and osteoporosis, but whether BMA can predict bone loss and fractures remains unknown. Using data from the Age Gene/Environment Susceptibility (AGES)-Reykjavik study, we investigated the associations between 1 H-MRS-based measures of vertebral bone marrow adipose tissue (BMAT), annualized change in bone density/ strength by quantitative computed tomography (QCT) and DXA, and secondarily, with incident clinical fractures and radiographic vertebral fractures among older adults. The associations between BMAT and annualized change in bone density/strength were evaluated using linear regression models, adjusted for age, body mass index (BMI), diabetes, estradiol, and testosterone. Cox proportional hazards models were used to evaluate the associations between baseline BMAT and incident clinical fractures, and logistic regression models for incident vertebral fractures. At baseline, mean AE SD age was 80.9 AE 4.2 and 82.6 AE 4.2 years in women (n = 148) and men (n = 150), respectively. Mean baseline BMAT was 55.4% AE 8.1% in women and 54.1% AE 8.2% in men. Incident clinical fractures occurred in 7.4% of women over 2.8 years and in 6.0% of men over 2.2 years. Incident vertebral fractures occurred in 12% of women over 3.3 years and in 17% of men over 2.7 years. Each 1 SD increase in baseline BMAT was associated with a 3.9 mg 2 /cm 4 /year greater loss of spine compressive strength index (p value = .003), a 0.9 mg/cm 3 /year greater loss of spine trabecular BMD (p value = .02), and a 1.2 mg/cm 3 /year greater loss of femoral neck trabecular BMD (p value = .02) in women. Among men, there were no associations between BMAT and changes in bone density/strength. There were no associations between BMAT and incident fractures in women or men. In conclusion, we found greater BMAT is associated with greater loss of trabecular bone at the spine and femoral neck, and greater loss of spine compressive strength, in older women.n 326 WOODS ET AL. 29. Kennell JA, MacDougald OA. Wnt signaling inhibits adipogenesis through beta-catenin-dependent and -independent mechanisms. J Biol Chem. 2005;280(25):24004-10. 30. Ma YH, Schwartz AV, Sigurdsson S, et al. Circulating sclerostin associated with vertebral bone marrow fat in older men but not women.

show abstract

“…A T-score between -1.0 and -2.5 SD indicates osteopenia [123]. In the case of risk factors, the presence of vertebral fractures should be evaluated by vertebral morphometry [124].…”

Section: Clinical Management Of Bone Health and Vitamin D Supplementamentioning

confidence: 99%

Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors

Altieri¹,

Dato

Modica

et al. 2020

Nutrients

View full text Add to dashboard Cite

Patients affected by gastroenteropancreatic–neuroendocrine tumors (GEP–NETs) have an increased risk of developing osteopenia and osteoporosis, as several factors impact on bone metabolism in these patients. In fact, besides the direct effect of bone metastasis, bone health can be affected by hormone hypersecretion (including serotonin, cortisol, and parathyroid hormone-related protein), specific microRNAs, nutritional status (which in turn could be affected by medical and surgical treatments), and vitamin D deficiency. In patients with multiple endocrine neoplasia type 1 (MEN1), a hereditary syndrome associated with NET occurrence, bone damage may carry other consequences. Osteoporosis may negatively impact on the quality of life of these patients and can increment the cost of medical care since these patients usually live with their disease for a long time. However, recommendations suggesting screening to assess bone health in GEP–NET patients are missing. The aim of this review is to critically analyze evidence on the mechanisms that could have a potential impact on bone health in patients affected by GEP–NET, focusing on vitamin D and its role in GEP–NET, as well as on factors associated with MEN1 that could have an impact on bone homeostasis.

show abstract

The Radiology of Osteoporotic Vertebral Fractures Revisited

Cited by 79 publications

References 63 publications

DIAGNOSIS OF ENDOCRINE DISEASE: Evaluation of bone fragility in endocrine disorders

DIAGNOSIS OF ENDOCRINE DISEASE: Evaluation of bone fragility in endocrine disorders

Greater Bone Marrow Adiposity Predicts Bone Loss in Older Women

Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors

Contact Info

Product

Resources

About